Fig. 8. TRIP6 potentiates RIP2- and Nod1-mediated Elk1 activation. (A) Effects of TRIP6 and its mutants on Elk1 activation. The detection of ERK activity was measured by Elk1 activity according to the PathDetect in vivo signal transduction pathway trans reporting systems protocols (Stratagene, La Jolla, CA). 293 cells (2x10⁵) were transfected with 0.5 µg pFR plasmid, 0.05 µg the trans-activating plasmid pFA-Elk1, 0.2 µg Rous sarcoma virus (RSV)/ß-galactosidase plasmid (as transfection control) and 0.2 µg plasmid encoding the indicated TRIP6 or its mutant. Luciferase and ß-galactosidase reporter assays were performed 16 hours after transfection. Luciferase activities were normalized on the basis of ß-galactosidase activities. (B) TRIP6 potentiates RIP2- and Nod1-mediated Elk1 activation. 293 cells (2x10⁵) were transfected with 0.5 µg pFR plasmid, 0.05 µg the trans-activating plasmid pFA-Elk1, 0.2 µg RSV/ß-galactosidase plasmid (as transfection control), 0.2 µg RIP2 or Nod1 plasmid and the indicated amount of TRIP6 expression plasmid. Luciferase and ß-galactosidase reporter assays were performed 16 hours after transfection. Luciferase activities were normalized on the basis of ß-galactosidase activities.